Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid

Jaffe, Glenn J.; Kaiser, Peter K.; Thompson, Desmond; Gibson, Andrea; Saroj, Namrata; Vitti, Robert; Berliner, Alyson J.; Heier, Jeffrey S.

doi:10.1016/j.ophtha.2016.05.016

Cited by 68 publications

(45 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, advanced analyses have meanwhile shown that such a 2q8 regimen misses optimal efficacy for a subgroup of patients. 23 Some patients will be overtreated, with unnecessary injections and associated expenses being incurred, and most importantly, some with an aggressive disease course will be undertreated and significantly lose vision. 23 Advanced prediction analysis, however, offers an individualized method to adjust retreatment schedules to disease activity while simultaneously reducing the socioeconomic burden of AMD therapy.…”

Section: Discussionmentioning

confidence: 99%

Prediction of Anti-VEGF Treatment Requirements in Neovascular AMD Using a Machine Learning Approach

Bogunović

Waldstein

Schlegl

et al. 2017

Invest. Ophthalmol. Vis. Sci.

128

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prediction of Anti-VEGF Treatment Requirements in Neovascular AMD Using a Machine Learning Approach

Bogunović

Waldstein

Schlegl

et al. 2017

Invest. Ophthalmol. Vis. Sci.

128

View full text Add to dashboard Cite

show abstract

“…Interestingly, we observed a decrease of intraretinal edema on average by 80% within the first 7 days after an intravitreal injection. In contrast, SRF/SRHM that are associated with a more favorable visual outcome [14,26,27] showed more prolonged decrease with significant changes between weeks 1 and 2. According to our data, IRF seem to decrease faster than SRF/SRHM [27] .…”

Section: Discussionmentioning

confidence: 74%

“…CNV activity of nAMD patients shows a high variability; persistent activity in a 4-week follow-up scheme is seen in a significant share of patients [14,23] . Data of early follow-up after anti-VEGF treatment would be helpful to better understand changes in retinal morphology, potential differences between anti-VEGF agents, analysis of early CNV recurrence, and the effect of early VEGF suppression in retinal and subretinal compartments.…”

Section: Introductionmentioning

confidence: 97%

Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents

Enders

Sitnilska²,

Altay³

et al. 2017

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To compare changes of retinal morphology in the first weeks following injection of anti-VEGF agents for neovascular age-related macular degeneration (nAMD). Procedures: In a prospective study 50 patients with active choroidal neovascularization secondary to nAMD were monitored weekly by spectral-domain optical coherence tomography for 3 weeks after treatment. Twenty-two patients received bevacizumab, 15 ranibizumab, and 13 aflibercept. Morphological parameters of retinal compartments were compared. Results: Mean central retinal thickness (391.22 ± 123.41 µm) was reduced by -26.15 µm (p < 0.001) after 1 week, by -12.54 µm (p < 0.001) after 2 weeks, and by -3.52 µm (p = 0.09) after 3 weeks. Mean intraretinal layer thickness changed only significantly between baseline and week 1 (p < 0.001). Mean subretinal thickness also decreased between weeks 1 and 2 (p = 0.01). Conclusions: Early morphological changes occur primarily in the first 14 days after treatment. This information could be clinically helpful to evaluate early non-response.

show abstract

“…Thus, aflibercept 2q4 may offer greater benefit to the subgroup of patients with early persistent retinal fluid compared to Rq4 and aflibercept 2q8. 30 Injections of all 3 anti-VEGF agents potentially pose risks of serious ocular adverse events, including endophthalmitis, retinal detachment, and subretinal and vitreous hemorrhage. However, as reported in the key clinical trials, rates of these events were approximately 1% or lower.…”

Section: ■■ Efficacy and Safety Of Anti-vegf Therapies: Results Of Kementioning

confidence: 99%

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration

Wykoff¹,

Clark²,

Nielsen³

et al. 2018

JMCP

104

View full text Add to dashboard Cite

PRIME Education is an independent medical education company and has been an accredited provider of continuing education for 23 years. There is no fee for this activity as it is sponsored by PRIME through an educational grant from Regeneron. All authors contributed to the writing and reviewing of the article. Wykoff reports consultancies/research grants from Alcon Laboratories, Genentech/Roche, Clearside, and Iconic Therapeutics; consultancies/honoraria, research grants, and speaker fees from Allergan and Regeneron; research grants from Allegro, Apellis, Aura, NEI, NIH, Novartis, OHR Pharmaceuticals, Ophthotech, pSivida, Roche, Santen, SciFluor, Tyrogenex; and consultancies for Alimera Sciences, Alnylam Pharmaceuticals, Bayer, DORC, ONL Therapeutics, Thrombogenics, and Valeant. Clark reports advisory board work, consultancies, research grants, and speaker fees from Genentech/Roche and Regeneron and consultancy for Bayer. Brill reports consultancies for Aries Pharma, Avella, BaroNova, Braeburn Pharmaceuticals, Cardinal Health, Endogastric Solutions, GeneNews, Halt Medical, Lumendi, Medtronic, Monteris Medical, Natera, Phosphorus, Rebiotix, Seno Medical, UCB, Vermillion, Echosens, and HAP Innovations. Brill is a shareholder in EndoChoice, GeneNews, SonarMD, and SynerZ and reports advisory board work with Nestle Health Sciences, Indivior Pharmaceuticals, Eli Lilly, Blue Earth Diagnostics, Bayer, and AstraZeneca. Nielson reports advisory board work/consultancy and research grants for Genentech/Roche; advisory board work and research grants from Regeneron; and research grants from Alcon and Ophthotech.

show abstract

Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid

Abstract: In patients with early persistent fluid, 2q4 may provide additional clinical benefit over 2q8 or Rq4.

Cited by 68 publications

References 13 publications

Prediction of Anti-VEGF Treatment Requirements in Neovascular AMD Using a Machine Learning Approach

Prediction of Anti-VEGF Treatment Requirements in Neovascular AMD Using a Machine Learning Approach

Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration

Contact Info

Product

Resources

About